Affinity Asset Advisors, LLC Viking Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.4 - $94.5 $4.35 Million - $23.6 Million	-250,000 Reduced 83.33%	50,000 $4.1 Million
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $4.78 Million - $7.99 Million	-322,249 Reduced 51.79%	300,000 $4.86 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $2.2 Million - $4.72 Million	272,249 Added 77.79%	622,249 $10.4 Million
Q4 2022 Feb 13, 2023	BUY	$2.72 - $9.4 $272,000 - $940,000	100,000 Added 40.0%	350,000 $3.29 Million
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $637,500 - $972,500	250,000 New	250,000 $680,000

480

66.2M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.